Log In
BCIQ
Print this Print this
 

MBG453

  Manage Alerts
Collapse Summary General Information
Company Novartis AG
DescriptionAnti-TIM3 checkpoint inhibitor
Molecular Target T cell immunoglobulin and mucin domain 3 (TIM3) (HAVCR2)
Mechanism of Action 
Therapeutic Modality 
Latest Stage of DevelopmentPhase I/II
Standard IndicationSolid tumors
Indication DetailsTreat solid tumors
Regulatory Designation
Partner

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today